1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Global Prostate Cancer Therapeutics Market to 2020

Global Prostate Cancer Therapeutics Market to 2020

  • May 2015
  • -
  • Igate Research
  • -
  • 76 pages

Prostate Cancer remains a top priority for health systems around the world as incidence level rises, fueled by growing and aging populations. The main drivers for the prostate cancer market are the increase in the global aging population, innovation in drugs and developments in genomics and proteomics. The prostate cancer market faces some hindrances as well such as the high cost of prostate cancer drugs, low success rate of clinical trials and side effects of treatments among others.


Global Prostate Cancer - Key Therapies Analysis: The global market for prostate cancer therapeutics is increasing, driven primarily by the growth in the hormonal therapy markets. Chemotherapy was the second leading therapy for prostate cancer in 2014. However, growth in the targeted therapy is predicted to push chemotherapy back at the third position, while immunotherapy for prostate cancer stands at the last positon in the prostate cancer therapeutics market.


Prostate Cancer Drugs Analysis: Zytiga leads the prostate cancer drugs market in 2014. Zytiga is facing stiff competition from Xtandi drugs which is expected to replace Zytiga as the leading prostate cancer drugs. In prostate cancer drugs market, Leuplin and Zoladex stand at the third and fourth position in 2014. The market share of both Leuplin and Zoladex is likely to plunge during the forecasting period. Lupron is standing at the fifth position. Bayer's targeted therapy drugs Xofigo is also rapidly catching up the market due to advantages such as increase in the overall survival and progression free survival with benign side effects profile.


iGATE RESEARCH report titled “Global Prostate Cancer Therapeutics Market to 2020” is a 76 page report with 43 Figures and 4 Tables. This report analyses the Prostate Cancer Therapy Market, Prostate Cancer Drugs Market, driving factors and challenges for prostate cancer market.

The 4 Prostate Cancer Therapy Market covered in the report are as follows:

1. Hormonal Therapy
2. Chemotherapy
3. Immunotherapy
4. Targeted Therapy

The above 4 Therapy has been further analyzed in terms of drugs sales and forecast (2011 - 2020):

1. Global Prostate Cancer - Hormonal Therapy Drugs Market

• Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists - Zytiga, Gonax

• Luteinizing Hormone-Releasing Hormone (LHRH) Analogs - Lupron, Zoladex, Decapeptyl, Eligard, Vantas, Leuplin

• Anti-Androgens - Casodex, Xtandi or MDV3100, Xtandi US or MDV3100


2. Global Prostate Cancer - Chemotherapy Drugs Market

1. Taxotere
2. Jevtana

3. Global Prostate Cancer - Immunotherapy Drugs Market

1. Provenge

4. Global Prostate Cancer - Targeted Therapy Drugs Market

1. Xofigo or Alpharadin


Source of Information

iGATE RESEARCH employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from Proprietary Information Database, Primary and Secondary Research Methodologies, and In house analysis by iGATE Research dedicated team of qualified professionals with deep industry experience and expertise.

Research Methodologies

Primary Research Methodologies: Questionnaires, Surveys, Interviews with Individuals, Small Groups, Telephonic Interview, etc.

Secondary Research Methodologies: Printable and Non-printable sources, Newspaper, Magazine and Journal Content, Government And NGO Statistics, white Papers, Information on the Web, Information from Agencies Such as Industry Bodies, Companies Annual Report, Government Agencies, Libraries And Local Councils and a large number of Paid Databases.

Table Of Contents

Global Prostate Cancer Therapeutics Market to 2020
1. Executive Summary

2. Global Prostate Cancer Therapeutics Market

3. Global Prostate Cancer Incidence

4. Global Prostate Cancer Therapeutics Market Share and Forecast (2011 - 2020)

4.1 Global Prostate Cancer - Therapy Market Share
4.2 Global Prostate Cancer - Drugs Market Share

5. Global Prostate Cancer Therapy Market and Forecast (2011 - 2020)

5.1 Global Prostate Cancer Hormonal Therapy Market and Forecast
5.2 Global Prostate Cancer Chemotherapy Market and Forecast
5.3 Global Prostate Cancer Immunotherapy Market and Forecast
5.4 Global Prostate Cancer Targeted Therapy Market and Forecast

6. Global Prostate Cancer - Hormonal Therapy Drugs Sales and Forecast to 2020

6.1 Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
6.1.1 Zytiga
6.1.2 Gonax/ Firmagon

6.2 Luteinizing Hormone-Releasing Hormone (LHRH) Analogs

6.2.1 Lupron
6.2.2 Zoladex
6.2.3 Decapeptyl
6.2.4 Eligard
6.2.5 Vantas
6.2.6 Leuplin

6.3 Anti-Androgens

6.3.1 Casodex
6.3.2 Xtandi or MDV3100
6.3.3 Xtandi US or MDV3100

7. Global Prostate Cancer - Chemotherapy Drugs Market

7.1 Taxotere
7.2 Jevtana

8. Global Prostate Cancer - Immunotherapy Drugs Market

8.1 Provenge

9. Global Prostate Cancer - Targeted Therapy Drugs Market

9.1 Xofigo or Alpharadin

10. Global Prostate Cancer Market - Driving Factors

10.1 Innovative Drugs Driving the Market
10.2 Advancement in Oncology Therapeutic Area
10.3 Developments in Genomics and Proteomics

11. Global Prostate Cancer Market - Challenges
11.1 High Cost of Prostate Cancer Drugs
11.2 Adverse Events of Treatment
11.3 Low Success Rate in Clinical Testing For Oncology Drugs


List of Figures:

Figure 2-1: Global - Prostate Cancer Therapeutics Market (Million US$), 2010 - 2014
Figure 2-2: Global - Forecast for Prostate Cancer Therapeutics Market (Million US$), 2015 - 2020
Figure 3-1: Global - Prostate Cancer Incidence (Number), 2007 - 2014
Figure 3-2: Global - Forecast for Prostate Cancer Incidence (Number), 2015 - 2020
Figure 5-1: Global Prostate Cancer - Hormonal Therapy Market (Million US$), 2011 - 2014
Figure 5-2: Global Prostate Cancer - Forecast for Hormonal Therapy Market (Million US$), 2015 - 2020
Figure 5-3: Global Prostate Cancer - Chemotherapy Market (Million US$), 2011 - 2014
Figure 5-4: Global Prostate Cancer - Forecast for Chemotherapy Market (Million US$), 2015 - 2020
Figure 5-5: Global Prostate Cancer - Immunotherapy Market (Million US$), 2011 - 2014
Figure 5-6: Global Prostate Cancer - Forecast for Immunotherapy Market (Million US$), 2015 - 2020
Figure 5-7: Global Prostate Cancer - Targeted Therapy Market (Million US$), 2013 - 2014
Figure 5-8: Global Prostate Cancer - Forecast for Targeted Therapy Market (Million US$), 2015 - 2020
Figure 6-1: Global - Zytiga Drugs Sales (Million US$), 2011 - 2014
Figure 6-2: Global - Forecast for Zytiga Drugs Sales (Million US$), 2015 - 2020
Figure 6-3: Global - Gonax/ Firmagon Drugs Sales (Million US$), 2012 - 2014
Figure 6-4: Global - Forecast for Gonax Drugs Sales (Million US$), 2015 - 2020
Figure 6-5: Global - Lupron Drugs Sales (Million US$), 2009 - 2014
Figure 6-6: Global - Forecast for Lupron Drugs Sales (Million US$), 2015 - 2020
Figure 6-7: Global - Zoladex Drugs Sales (Million US$), 2009 - 2014
Figure 6-8: Global - Forecast for Zoladex Drugs Sales (Million US$), 2015 - 2020
Figure 6-9: Global - Decapeptyl Drugs Sales (Million US$), 2009 - 2014
Figure 6-10: Global - Forecast for Decapeptyl Drugs Sales (Million US$), 2015 - 2020
Figure 6-11: Global - Eligard Drugs Sales (Million US$), 2009 - 2014
Figure 6-12: Global - Forecast for Eligard Drugs Sales (Million US$), 2015 - 2020
Figure 6-13: Global - Vantas Drugs Sales (Million US$), 2009 - 2014
Figure 6-14: Global - Forecast for Vantas Drugs Sales (Million US$), 2015 - 2020
Figure 6-15: Global - Leuplin Drugs Sales (Million US$), 2009 - 2014
Figure 6-16: Global - Forecast for Leuplin Drugs Sales (Million US$), 2015 - 2020
Figure 6-17: Global - Casodex Drugs Sales (Million US$), 2009 - 2014
Figure 6-18: Global - Forecast for Casodex Drugs Sales (Million US$), 2015 - 2020
Figure 6-19: Global - Xtandi or MDV3100 Drugs Sales (Million US$), 2012 - 2014
Figure 6-20: Global - Forecast for Xtandi or MDV3100 Drugs Sales (Million US$), 2015 - 2020
Figure 6-21: Global - Xtandi US or MDV3100 Drugs Sales (Million US$), 2012 - 2014
Figure 6-22: Global - Forecast for Xtandi US or MDV3100 Drugs Sales (Million US$), 2015 - 2020
Figure 7-1: Global - Taxotere Drugs Sales (Million US$), 2011 - 2014
Figure 7-2: Global - Forecast for Taxotere Drugs Sales (Million US$), 2015 - 2020
Figure 7-3: Global - Jevtana Drugs Sales (Million US$), 2010 - 2014
Figure 7-4: Global - Forecast for Jevtana Drugs Sales (Million US$), 2015 - 2020
Figure 8-1: Global - Provenge Drugs Sales (Million US$), 2011 - 2014
Figure 8-2: Global - Forecast for Provenge Drugs Sales (Million US$), 2015 - 2020
Figure 9-1: Global - Xofigo or Alpharadin Drugs Sales (Million US$), 2013 - 2014
Figure 9-2: Global - Forecast for Xofigo or Alpharadin Drugs Sales (Million US$), 2015 - 2020
Figure 11-1: Therapeutic Categories - Overall Success Rate from Phase 1 through Likelihood of Approval (Percent), 2004 - 2010

List of Tables:

Table 4-1: Global - Prostate Cancer Therapy Market Share (Percent), 2011 - 2014
Table 4-2: Global - Forecast for Prostate Cancer Therapy Market Share (Percent), 2015 - 2020
Table 4-3: Global - Prostate Cancer Drugs Market Share (Percent), 2011 - 2014
Table 4-4: Global - Forecast for Prostate Cancer Drugs Market Share (Percent), 2015 - 2020

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.